
Ambalal Sarabhai Enterprises Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target
Ambalal Sarabhai Enterprises CMP Rs.31. Q1 FY27E revenue Rs.46-53 Cr. PAT estimate Rs.4-5 Cr. 12-month target Rs.30-34.
Updated: 10 Jul 2026 • 10:48 am
Posted by:

Ambalal Sarabhai Enterprises Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Ambalal Sarabhai Enterprises shares trading at Rs.31 against a market capitalisation of Rs.241 Cr and a price-to-earnings multiple of Not meaningful. As a pharmaceuticals and life sciences name on the NSE and BSE, Ambalal Sarabhai Enterprises enters the Ambalal Sarabhai Enterprises Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.
This Ambalal Sarabhai Enterprises Q1 Results FY27 preview is built on a trailing-growth framework applied to the company's Q1 FY26 base of Rs.49 Cr revenue and Rs.8 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company's own guidance once released.
Get Free Investment Predictions and Ambalal Sarabhai Enterprises Research at Univest
About Ambalal Sarabhai Enterprises
Ambalal Sarabhai Enterprises (NSE: AMBALALSA) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings. Ahead of the Ambalal Sarabhai Enterprises Q1 Results FY27 print, the company's most recent reported quarter (Q4 FY26) shows revenue of Rs.68 Cr and net profit of Rs.6 Cr, forming the base against which the Ambalal Sarabhai Enterprises Q1 Results FY27 estimates in this article are built. This Ambalal Sarabhai Enterprises Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company's own disclosures.
Ambalal Sarabhai Enterprises Q1 FY27 Estimates
| Metric | Q1 FY27E (Range) | Q1 FY26 Actual | YoY Growth |
|---|---|---|---|
| Revenue (Rs. Cr) | 46-53 | 49 | +2.5% |
| Net Profit / PAT (Rs. Cr) | 4-5 | 8 | -50.0% |
| Results Date | July-August 2026 (indicative) | ||
| 12-Month Target (Uniresearch Estimate) | Rs.30-34 | ||
Key Catalysts to Watch
1. CDMO Pipeline Visibility
Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Ambalal Sarabhai Enterprises's Q1 FY27 results and FY27 guidance. The market's reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Ambalal Sarabhai Enterprises share price target or faces renewed pressure.
2. New Product Approvals
New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Ambalal Sarabhai Enterprises's Q1 FY27 results and FY27 guidance. The market's reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Ambalal Sarabhai Enterprises share price target or faces renewed pressure.
3. Capacity Scale-Up
Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Ambalal Sarabhai Enterprises's Q1 FY27 results and FY27 guidance. The market's reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Ambalal Sarabhai Enterprises share price target or faces renewed pressure.
Download the Univest iOS App or Univest Android App to track Ambalal Sarabhai Enterprises's live price and Q1 FY27 result updates.
Key Risks to the Ambalal Sarabhai Enterprises Q1 Results FY27 Outlook
- Pricing pressure in key export markets, particularly the US generics segment.
- Regulatory or plant compliance issues affecting supply continuity.
- R&D and capacity expansion costs weighing on near-term profitability.
Q4 FY26 Performance Context for the Ambalal Sarabhai Enterprises Q1 Results FY27 Print
Ambalal Sarabhai Enterprises closed Q4 FY26 with revenue of Rs.68 Cr and net profit of Rs.6 Cr, a year-on-year revenue change of +2.5% and PAT change of +2507.4% versus Q4 FY25. This base underpins the Ambalal Sarabhai Enterprises Q1 Results FY27 projection used in this preview and should be read alongside the company's own Ambalal Sarabhai Enterprises Q1 Results FY27 commentary once reported.
Technical Analysis Ahead of Ambalal Sarabhai Enterprises Q1 Results FY27
Ambalal Sarabhai Enterprises shares last traded at Rs.31. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.
Share Price Target Based on the Ambalal Sarabhai Enterprises Q1 Results FY27 Outlook
3-6 Month Target
Over a 3-6 month horizon, the Ambalal Sarabhai Enterprises Q1 Results FY27 trailing-growth framework points to a range of Rs.30-33 for Ambalal Sarabhai Enterprises, contingent on the Ambalal Sarabhai Enterprises Q1 Results FY27 print matching or beating the trailing growth trend.
12-Month Target
The 12-month target (Uniresearch estimate) tied to this Ambalal Sarabhai Enterprises Q1 Results FY27 view for Ambalal Sarabhai Enterprises works out to Rs.30-34, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Ambalal Sarabhai Enterprises Q1 Results FY27, not a formal Buy or Sell call.
FY27-28 Outlook
Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Ambalal Sarabhai Enterprises Q1 Results FY27 analysis would put Ambalal Sarabhai Enterprises in a Rs.31-37 range, though this is sensitive to sector-wide demand, cost trends and any change in the company's competitive position.
What to Watch in the Ambalal Sarabhai Enterprises Q1 Results FY27 Print
- Revenue and PAT versus the Ambalal Sarabhai Enterprises Q1 Results FY27 estimate range in this preview.
- Management commentary on FY27 growth guidance and margin trajectory relevant to the Ambalal Sarabhai Enterprises Q1 Results FY27 narrative.
- Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
- Pricing pressure in key export markets, particularly the US generics segment
Conclusion on Ambalal Sarabhai Enterprises Q1 Results FY27
Ambalal Sarabhai Enterprises enters the Q1 FY27 results season trading at Rs.31, with the 12-month Uniresearch target range of Rs.30-34 reflecting a tracking stance. Investors tracking the Ambalal Sarabhai Enterprises Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Ambalal Sarabhai Enterprises Q1 Results FY27
When are Ambalal Sarabhai Enterprises Q1 FY27 results expected?
Ans. Ambalal Sarabhai Enterprises's Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.
What is the Ambalal Sarabhai Enterprises Q1 FY27 revenue estimate?
Ans. The Uniresearch trailing-growth estimate for Ambalal Sarabhai Enterprises's Q1 FY27 revenue is Rs.46-53 Cr, based on the Q1 FY26 base of Rs.49 Cr.
What is the Ambalal Sarabhai Enterprises share price target?
Ans. The 12-month Uniresearch estimate for Ambalal Sarabhai Enterprises share price target is Rs.30-34, based on trailing growth and current valuation multiples.
Is Ambalal Sarabhai Enterprises a good buy before Q1 FY27 results?
Ans. Ambalal Sarabhai Enterprises is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.
What should investors watch in Ambalal Sarabhai Enterprises's Q1 FY27 results?
Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.
Where can I track Ambalal Sarabhai Enterprises share price live?
Ans. Ambalal Sarabhai Enterprises share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.
Recent Articles

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs UTI Master Equity Plan: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
28 July 2026

Reliance Equity Linked Saving Fund - Series I vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
28 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs UTI Master Equity Plan: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
Reliance Equity Linked Saving Fund - Series I vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
SBI Long Term Advantage Fund - Series VI IDCW vs Bank of India Mid Cap Tax Fund Series 2 Regular Growth: NAV, Returns and Maturity Status Compared
Popular this week
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs UTI Master Equity Plan: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
Reliance Equity Linked Saving Fund - Series I vs Bank of India Mid Cap Tax Fund Series 1 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Direct Plan IDCW Payout vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
SBI Long Term Advantage Fund - Series VI IDCW vs Bank of India Mid Cap Tax Fund Series 2 Regular Growth: NAV, Returns and Maturity Status Compared

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





